09 Nov 2021
14:00 CET |
TRANSGENE |
Transgene et BioInvent présentent des données précliniques soulignant la forte activité antitumorale du virus oncolytique BT-001 au SITC 2021
|
20103010 Biotechnology |
New |
04 Nov 2021
17:45 CET |
TRANSGENE |
Transgene Reports Business Update and Q3 2021 Financial Position
|
20103010 Biotechnology |
Income |
04 Nov 2021
17:45 CET |
TRANSGENE |
Transgene publie sa situation financière et fait un point sur son activité au troisième trimestre 2021
|
20103010 Biotechnology |
Income |
01 Oct 2021
15:00 CEST |
TRANSGENE |
Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021
|
20103010 Biotechnology |
Products and services |
01 Oct 2021
15:00 CEST |
TRANSGENE |
Transgene et BioInvent présenteront des données précliniques sur le virus oncolytique BT-001 au SITC 2021
|
20103010 Biotechnology |
Products and services |
22 Sep 2021
17:45 CEST |
TRANSGENE |
Progression des deux plateformes innovantes de Transgene et visibilité financière étendue à fin 2023
|
20103010 Biotechnology |
Other financial transaction |
22 Sep 2021
17:45 CEST |
TRANSGENE |
Mise à disposition du Rapport Financier Semestriel au 30 juin 2021
|
20103010 Biotechnology |
Income |
22 Sep 2021
17:45 CEST |
TRANSGENE |
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
|
20103010 Biotechnology |
Other financial transaction |
22 Sep 2021
17:45 CEST |
TRANSGENE |
Availability of Transgene’s Half-Year Financial Report as of June 30, 2021
|
20103010 Biotechnology |
Income |
16 Sep 2021
08:30 CEST |
TRANSGENE |
Transgene présente des données de Phase I confirmant le potentiel du virus oncolytique TG6002
|
20103010 Biotechnology |
Other subject |
16 Sep 2021
08:30 CEST |
TRANSGENE |
Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002
|
20103010 Biotechnology |
Other subject |
13 Sep 2021
08:00 CEST |
TRANSGENE |
Transgene Announces Upcoming Investor Meetings
|
20103010 Biotechnology |
Meetings / events |
13 Sep 2021
08:00 CEST |
TRANSGENE |
Transgene annonce ses prochaines rencontres avec les investisseurs
|
20103010 Biotechnology |
Meetings / events |
01 Sep 2021
17:45 CEST |
TRANSGENE |
Transgene Participates in New Cancer Research Consortium
|
20103010 Biotechnology |
Other subject |
01 Sep 2021
17:45 CEST |
TRANSGENE |
Transgene participe à un nouveau consortium de recherche contre le cancer
|
20103010 Biotechnology |
Other subject |
06 Jul 2021
18:00 CEST |
TRANSGENE |
Transgene: Balance Sheet of the Liquidity Contract With Natixis Oddo BHF SCA as of June 30, 2021
|
20103010 Biotechnology |
Other financial transaction |
06 Jul 2021
18:00 CEST |
TRANSGENE |
Transgene : Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 30 juin 2021
|
20103010 Biotechnology |
Other financial transaction |
28 Jun 2021
07:00 CEST |
TRANSGENE |
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
|
20103010 Biotechnology |
Products and services |
28 Jun 2021
07:00 CEST |
TRANSGENE |
Premier patient inclus au Royaume-Uni dans l’essai de Phase I de TG4050 (plateforme myvac®), l’immunothérapie individualisée de Transgene
|
20103010 Biotechnology |
Products and services |
24 Jun 2021
17:45 CEST |
TRANSGENE |
Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers
|
20103010 Biotechnology |
Other subject |
24 Jun 2021
17:45 CEST |
TRANSGENE |
Transgene : Inclusion du premier patient dans l’essai de Phase II de TG4001 + avelumab vs avelumab dans les cancers anogénitaux HPV16-positifs
|
20103010 Biotechnology |
Other subject |
22 Jun 2021
07:00 CEST |
TRANSGENE |
Transgene Announces the Success of Its Capital Increase via a Private Placement
|
20103010 Biotechnology |
Share introduction and issues |
22 Jun 2021
07:00 CEST |
TRANSGENE |
Transgene annonce le succès de son augmentation de capital par placement privé
|
20103010 Biotechnology |
Share introduction and issues |
21 Jun 2021
18:16 CEST |
TRANSGENE |
Transgene lance une augmentation de capital par placement privé
|
20103010 Biotechnology |
Other subject |
21 Jun 2021
18:16 CEST |
TRANSGENE |
Transgene Launches a Capital Increase via a Private Placement
|
20103010 Biotechnology |
Other subject |
08 Jun 2021
17:45 CEST |
TRANSGENE |
Transgene renforce les droits de propriété intellectuelle de ses virus oncolytiques codant pour des inhibiteurs de points de contrôle (ICI)
|
20103010 Biotechnology |
Other subject |
08 Jun 2021
17:45 CEST |
TRANSGENE |
Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
|
20103010 Biotechnology |
Other subject |
27 May 2021
08:30 CEST |
TRANSGENE |
Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors
|
20103010 Biotechnology |
Other subject |
27 May 2021
08:30 CEST |
TRANSGENE |
Transgene et BioInvent obtiennent l’autorisation IND « Investigational New Drug » de la FDA américaine pour BT-001, un virus oncolytique contre les tumeurs solides
|
20103010 Biotechnology |
Other subject |
26 May 2021
17:45 CEST |
TRANSGENE |
Transgene: Combined General Meeting of May 26, 2021
|
20103010 Biotechnology |
General meeting / Board Meeting |
26 May 2021
17:45 CEST |
TRANSGENE |
Transgene : Assemblée Générale Mixte du 26 mai 2021
|
20103010 Biotechnology |
General meeting / Board Meeting |